Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289015 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
A Phase 3 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 855
- Enrollment target
NCT01289015: Completed Phase 3 study, sponsored by Merz North America.
NCT01289015 is a Phase 3 study that has completed, run by Merz North America. The registered enrollment target is 855 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01289015, a Phase 3 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 855 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.
Primary Outcome
The primary efficacy comparison between NAFT-600 gel and placebo will be based on the percentage of subjects at Week 6 with complete cure of interdigital tinea pedis. Complete cure is defined as negative mycology results (dermatophyte culture and KOH) and the absence of erythema, scaling, and pruritus.
Interventions
- DRUG Placebo
- DRUG NAFT-600 ( naftin 2 % gel )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 855 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
What the finished NCT01289015 record still lists
NCT01289015 is an interventional study that assigns participants to a tested intervention. The registered 855 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01289015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01289015 about?
NCT01289015 is a clinical study titled "Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis". The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.
What is the current status of trial NCT01289015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 855 participants. The study started on 2011-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01289015?
The interventions under investigation include: Placebo (DRUG), NAFT-600 ( naftin 2 % gel ) (DRUG).
Who is sponsoring clinical trial NCT01289015?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01289015's enrollment target sits among peer trials
855 384th of 2000 higher than 1,617 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia